SCHEMBL13367666

SCHEMBL13367666

COc1ccc(N(C)c2ccc(-c3ccc4ccccc4c3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
CYP2A6 P11509 1/20 0.53
CYP11B2 P19099 3/20 0.49
CYP11B1 P15538 2/20 0.49
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
ABL1 P00519 1/20 0.46
ABCB1 P08183 1/20 0.46
BCR P11274 1/20 0.46
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
EGFR P00533 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12048454 0.89 CYP1A2 (0.49) CYP1A2CYP2A6CYP11B2CYP11B1ABL1
SCHEMBL12048751 0.88 CYP1A2 (0.59) CYP1A2CYP2A6NPC1RAB9ASMN1; SMN2
SCHEMBL1896522 0.88 CYP1A2 (0.68) CYP1A2CYP2A6CYP11B2CYP11B1HSD17B1
SCHEMBL12048328 0.86 CYP1A2 (0.46) CYP1A2CYP2A6CYP11B2CYP11B1NPC1
SCHEMBL12048556 0.86 CYP1A2 (0.46) CYP1A2CYP2A6CYP11B2CYP11B1ABL1
SCHEMBL12048045 0.86 CYP1A2 (0.46) CYP1A2CYP2A6CYP11B2CYP11B1ABL1
SCHEMBL13367672 0.86 ESR1 (0.52) CYP1A2CYP11B2CYP11B1HSD17B1HSD17B2
SCHEMBL13367361 0.86 ESR1 (0.52) CYP1A2CYP2A6CYP11B2CYP11B1HSD17B1
SCHEMBL19844105 0.86 ESR1 (0.52) CYP1A2CYP11B2CYP11B1HSD17B1HSD17B2
SCHEMBL12048595 0.85 ABL1 (0.43) CYP1A2CYP2A6CYP11B2CYP11B1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100108997-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100108997-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OR10J3, OCIAD1, OCIAD2 CYP1A2 1021/4885CYP2A6 2286/4885CYP11B2 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.